peptidase is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
=== Synthetic genomics === The formation of animals with a chemically manufactured (minimal) genome is another facet of synthetic biology that is highlighted by synthetic genomics. This area of synthetic biology has been made possible by ongoing advancements in DNA synthesis technology, which now makes it feasible to produce DNA molecules with thousands of base pairs at a reasonable cost. The goal is to combine these molecules into complete genomes and transplant them into living cells, replacing the host cell's genome and reprogramming its metabolism to perform different functions. Scientists have previously demonstrated the potential of this approach by creating infectious viruses by synthesising the genomes of multiple viruses. These significant advances in science and technology triggered the initial public concerns concerning the risks associated with this technology. A simple genome might also work as a "chassis genome" that could be enlarged quickly by gene inclusion created for particular tasks. Such "chassis creatures" would be more suited for the insertion of new functions than wild organisms since they would have fewer biological pathways that could potentially conflict with the new functionalities in addition to having specific insertion sites. Synthetic genomics strives to create creatures with novel "architectures," much like the bioengineering method. It adopts an integrative or holistic perspective of the organism.
It even exceeded the brutal violence unleashed by Hafez al-Assad during the Hama Massacre. By pursuing scorched-earth policies to crush the armed resistance, Bashar had destroyed majority of Syria's civilian, cultural and economic infrastructure. Unlike his father, Bashar killed far more Syrian civilians and has also lost significant amount of his political independence to foreign actors like Russia and Iran. In April 2017, the U.S. Navy carried out a missile attack against a Syrian air base which had been used to conduct a chemical weapons attack on Syrian civilians. This attack is also known as the 2017 Shayrat missile strike. In 2018, coalition forces including United States, France, and the United Kingdom also carried out a series of military strikes in Syria.
A laboratory information management system (LIMS), sometimes referred to as a laboratory information system (LIS) or laboratory management system (LMS), is a software-based solution with features that support a modern laboratory's operations. They tend to be handled by inventory laboratory technicians. Key features include—but are not limited to—workflow and data tracking support, flexible architecture, and data exchange interfaces, which fully "support its use in regulated environments". The features and uses of a LIMS have evolved over the years from simple sample tracking to an enterprise resource planning tool that manages multiple aspects of laboratory informatics. There is no useful definition of the term "LIMS" as it is used to encompass a number of different laboratory informatics components. The spread and depth of these components is highly dependent on the LIMS implementation itself. All LIMSs have a workflow component and some summary data management facilities but beyond that there are significant differences in functionality. Historically the LIMyS, LIS, and process development execution system (PDES) have all performed similar functions. The term "LIMS" has tended to refer to informatics systems targeted for environmental, research, or commercial analysis such as pharmaceutical or petrochemical work. "LIS" has tended to refer to laboratory informatics systems in the forensics and clinical markets, which often required special case management tools.
RNA, in contrast, forms large and complex 3D tertiary structures reminiscent of proteins, as well as the loose single strands with locally folded regions that constitute messenger RNA molecules. Those RNA structures contain many stretches of A-form double helix, connected into definite 3D arrangements by single-stranded loops, bulges, and junctions. Examples are tRNA, ribosomes, ribozymes, and riboswitches. These complex structures are facilitated by the fact that RNA backbone has less local flexibility than DNA but a large set of distinct conformations, apparently because of both positive and negative interactions of the extra OH on the ribose. Structured RNA molecules can do highly specific binding of other molecules and can themselves be recognized specifically; in addition, they can perform enzymatic catalysis (when they are known as "ribozymes", as initially discovered by Tom Cech and colleagues).
Sources: en.wikipedia.org
== References == Aeschliman, M.D (28 March 2005). "Murderous Science". The National Review. Vol. LVII, no. 5. pp. 49–50. Baldwin, Peter (1990). Reworking the Past: Hitler, the Holocaust, and the Historians' Debate. Boston: Beacon Press. Bessel, Richard (August 1990). "Detlev J.K. Peukert". German History. 8 (3): 321–324. doi:10.1093/gh/8.3.321. Crew, David (May 1992). "The Pathologies of Modernity: Detlev Peukert on Germany's Twentieth Century". Social History. 17 (2): 319–328. doi:10.1080/03071029208567840. Kater, Michael (May 1992). "Conflict in Society and Culture: The Challenge of National Socialism". German Studies Review. 15 (2): 289–294. doi:10.2307/1431167. JSTOR 1431167. Kershaw, Ian (2000). The Nazi Dictatorship Problems and Perspectives of Interpretation. London: Arnold Press. ISBN 0-340-76028-1. Lindemann, Albert (February 1982). "Review of Die KPD im Widerstand Verfolgung und Untergrundarbeit am Rhein und Ruhr, 1933-1945". The American Historical Review. 82 (1): 205. doi:10.2307/1863393. JSTOR 1863393. Nolan, Mary (Spring–Summer 1988). "The Historikerstreit and Social History". New German Critique (44): 1–80. Pendas, Devin; Roseman, Mark (2017). Beyond the Racial State: Rethinking Nazi Germany. Cambridge: Cambridge University Press. ISBN 978-1107165458. Peukert, Detlev (1987). Conformity, Opposition and Racism in Everyday Life. New Haven: Yale University Press. ISBN 0300038631. Peukert, Detlev (1994). "The Genesis of the 'Final Solution' from the Spirit of Science". In Thomas Childers; Jane Caplan (eds.). Reevaluating the Third Reich. New York: Holmes & Meier.
=== Palliative care === Palliative care is specialized medical care that focuses on providing patients with relief from the symptoms, pain, and stress of a serious illness, such as cirrhosis. The goal of palliative care is to improve quality of life for both the patient and the patient's family, and it is appropriate at any stage and for any type of cirrhosis. Especially in the later stages, people with cirrhosis experience significant symptoms such as abdominal swelling, itching, leg edema, and chronic abdominal pain, which would be amenable to treatment through palliative care. Because the disease is not curable without a transplant, palliative care can also help with discussions regarding the person's wishes concerning health care power of attorney, do not resuscitate decisions and life support, and potentially hospice. Despite proven benefit, people with cirrhosis are rarely referred to palliative care.
High affinity copper uptake protein 1 (CTR1) is a transmembrane protein that is encoded by the SLC31A1 gene in humans. Copper is an element essential for life, but excessive copper can be toxic or even lethal to the cell. Therefore, cells have developed sophisticated ways to maintain a critical copper balance, with the intake, export, and intracellular compartmentalization or buffering of copper strictly regulated. The 2 related genes ATP7A and ATP7B, responsible for the human diseases Menkes syndrome and Wilson disease, respectively, are involved in copper export. In S. cerevisiae, the copper uptake genes CTR1, CTR2, and CTR3 have been identified, and in human the CTR1 and CTR2 (MIM 603088) genes have been identified.
Sources: en.wikipedia.org
==== MeSH E05.601.495 – immunoassay ==== MeSH E05.601.495.320 – immunoblotting MeSH E05.601.495.320.200 – blotting, western MeSH E05.601.495.350 – immunoenzyme techniques MeSH E05.601.495.350.170 – enzyme-linked immunosorbent assay MeSH E05.601.495.350.180 – enzyme multiplied immunoassay technique MeSH E05.601.495.380 – immunosorbent techniques MeSH E05.601.495.380.360 – enzyme-linked immunosorbent assay MeSH E05.601.495.380.810 – radioallergosorbent test MeSH E05.601.495.380.825 – radioimmunoprecipitation assay MeSH E05.601.495.380.830 – radioimmunosorbent test MeSH E05.601.495.639 – radioimmunoassay MeSH E05.601.495.639.405 – immunoradiometric assay MeSH E05.601.495.639.810 – radioallergosorbent test MeSH E05.601.495.639.825 – radioimmunoprecipitation assay MeSH E05.601.495.639.830 – radioimmunosorbent test
The university's mascots are a pair of anthropomorphized wildcats named Wilbur and Wilma. The human figures behind Wilbur and Wilma are kept secret through the year as the mascots appear only in costume. In 1986, Wilbur married his longtime wildcat girlfriend, Wilma. Together, Wilbur and Wilma appear along with the cheerleading squad at most Wildcat sporting events. Arizona's first mascot was a real desert bobcat named "Rufus Arizona", introduced in 1915.
== History == The company was founded in 1929 by Dharampal Sugandhi in Chandni Chowk, Delhi, as a perfumery business producing incense sticks, rose water, and tobacco products. In 1958, Satyapal Sugandhi introduced the BABA tobacco brand. During the 1980s, the group diversified into packaged foods with the launch of Catch Salt & Pepper (1987), followed by Catch Natural Spring Water in 1999. The group's subsequent launches included confectionery products under brands such as Rajnigandha, Pass Pass, and Pulse Candy. In 2019, the DS Group acquired an 11–18% stake in the Switzerland-based Lalique Group . In 2023, it introduced the Swiss chocolate brand Läderach to India and acquired the Indian confectionery brand LuvIt.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.